DaVita
Provides dialysis and integrated kidney care across U.S. and international clinic networks.
Something off on this page? Send us feedback.
Profile
Provides outpatient, home, and hospital dialysis, related laboratory services, and integrated kidney care. Most revenue comes from U.S. dialysis; government programs cover most patients, while higher-paying commercial contracts generate nearly all dialysis profit.
Provides outpatient, home-based, and hospital inpatient dialysis for people with end-stage kidney disease, with related laboratory and administrative services. U.S. dialysis is the largest line of business, supported by a nationwide clinic network and local nephrologist relationships.
Extends beyond dialysis through Integrated Kidney Care, which coordinates chronic and end-stage kidney disease care under fee-based, shared-savings, performance, and capitated arrangements. International operations run dialysis centers across Latin America, Europe, Asia, and the Middle East, while smaller ancillary businesses cover clinical research and transplant software.
A broad care network, trained clinical staff, and data-enabled coordination support recurring treatments across care settings. Revenue depends on Medicare and other government reimbursement, higher-paying commercial contracts, patient referrals, labor and supply costs, and compliance with healthcare billing, referral, and value-based-care rules.
Company facts
Key statistics
Year to date +57.8% · Average volume (30d) 878.3K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 7, 2026 | Truist Financial | Target | $250 | $215 | ||
| Aug 7, 2026 | Cowen & Co. | Upgrade | Hold | Buy | ||
| Aug 7, 2026 | Raymond James | Target | $220 | |||
| Aug 7, 2026 | Oppenheimer | Target | $220 | |||
| Aug 7, 2026 | TD Cowen | Upgrade | Hold | Buy |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 4, 2026Q2 FY26 | $3.88 | $4.02 | +3.6% | $3.50B | $3.55B | +1.7% | −17.24% |
| May 5, 2026Q1 FY26 | $2.41 | $2.87 | +19.1% | $3.36B | $3.42B | +1.8% | +23.46% |
| Feb 2, 2026Q4 FY25 | $3.24 | $3.40 | +4.9% | $3.51B | $3.62B | +3.2% | +21.17% |
| Oct 29, 2025Q3 FY25 | $3.17 | $2.51 | −20.8% | $3.43B | $3.42B | −0.2% | −6.17% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $3.22B | $3.38B | $3.42B | $3.62B | $3.42B | $3.55B | |
| Gross profit | $983.9M | $1.12B | $1.09B | $1.02B | $1.07B | $1.16B | |
| Operating income | $438.9M | $537.8M | $505.8M | $551.2M | $481.9M | $570.8M | |
| Net income | $162.9M | $199.3M | $150.3M | $234.2M | $197.5M | $265.4M | |
| Diluted EPS | $2.00 | $2.58 | $2.04 | $2.45 | $2.87 | $4.02 | |
| Gross margin | 30.5% | 33.1% | 31.8% | 28.3% | 31.4% | 32.7% | |
| Operating margin | 13.6% | 15.9% | 14.8% | 15.2% | 14.1% | 16.1% |
Fiscal years (4-quarter sums)FY21 $11.62B · FY22 $11.61B · FY23 $12.14B · FY24 $12.82B · FY25 $13.64B
Revenue by product · Q4 FY25
Balance sheet, Jun 30, 2026Cash & short-term investments $688.9M · Total debt $10.78B · Total assets $17.71B · Shareholders' equity −$765.1M
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 64.20M · Float 62.87M · 97.9% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Berkshire Hathaway Inc · 10 percent owner | 28.70M | 44.70% | Form 4 | Aug 4, 2026 |
| BlackRock, Inc. | 2.46M | 3.83% | 13F | Aug 7, 2026 |
| Vanguard Capital Management LLC | 2.10M | 3.27% | 13F | Aug 13, 2026 |
| Morgan Stanley | 1.60M | 2.49% | 13F | Aug 13, 2026 |
| Vanguard Portfolio Management LLC | 1.38M | 2.15% | 13F | Aug 13, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 31, 2026 | Berkshire Hathaway Inc | 10 percent owner | −182,980 | $199.55 |
| Jun 16, 2026 | Javier Rodriguez | director, officer: Chief Executive Officer | −39,407 | $209.28 |
| Jun 15, 2026 | Javier Rodriguez | director, officer: Chief Executive Officer | −30,000 | $209.50 |
| Jun 15, 2026 | Kathleen Alyce Waters | officer: Chief Legal & Pub. Affairs Off | −15,405 | $208.40 |
| May 15, 2026 | James O. Hearty | officer: Chief Compliance Officer | −15,000 | $193.98 |
Peers
- Fresenius Medical Care (ADR)
Direct dialysis-care and products peer across clinics, home care, and VBC
- UnitedHealth Group
Integrated kidney-care overlap through Optum and UnitedHealthcare
- CVS Health
Integrated-care platform overlapping kidney value-based care
- Humana
MA-led kidney-care risk and senior primary-care overlap
- Outset Medical
Hospital/home dialysis tech challenging outsourced service models
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| DaVita | $181.97 | +0.69% | $11.60B | 15.9 | 11.4 | 0.8 | +5.2% |
| Fresenius Medical Care (ADR) | $23.10 | +0.13% | $12.41B | 11.9 | 16.7 | 0.5 | −0.7% |
| UnitedHealth Group | $392.50 | −0.12% | $356.86B | 25.3 | 18.4 | 0.8 | +0.4% |
| CVS Health | $93.07 | +0.02% | $118.74B | 24.6 | 11.5 | 0.3 | +7.3% |
| Humana | $386.23 | +0.16% | $46.30B | 36.5 | 31.2 | 0.3 | +26.2% |
| Outset Medical | $3.91 | −0.87% | $73.0M | — | — | 0.6 | +0.7% |
| Median | 24.9 | 17.6 | 0.5 | +0.7% |